Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

about

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

Item

http://www.wikidata.org/entity/Q42374224

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@en

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@nl

type

Item

label

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@en

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@nl

prefLabel

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@en

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@nl

P1476

Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

@en

P2093

Jessica E Sagers

http://www.w3.org/2001/XMLSchema#string

Konstantina M Stankovic

http://www.w3.org/2001/XMLSchema#string

Sangeeta N Bhatia

http://www.w3.org/2001/XMLSchema#string

Yin Ren

http://www.w3.org/2001/XMLSchema#string

P2860

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Cell surface tumor endothelial markers are conserved in mice and humans

Drug penetration in solid tumours

Integrins in cancer: biological implications and therapeutic opportunities

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

High interstitial fluid pressure - an obstacle in cancer therapy

Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

P2888

s41598-017-13032-9

P304

12922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-13032-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lukas D Landegger

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092092373

http://www.w3.org/2001/XMLSchema#string

P698

29018206

http://www.w3.org/2001/XMLSchema#string

P932

5635039

http://www.w3.org/2001/XMLSchema#string